This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, K. K. Articles by Klibanski, A. Search for Related Content PubMed PubMed Citation Articles by Miller, K. K. Articles by Klibanski, A.

Effects of Risedronate on Bone Density in Anorexia Nervosa

Neuroendocrine Unit (K.K.M., K.A.G., J.M., S.G., R.Y., A.K.), and the Eating Disorders Unit (D.B.H.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; and Wilkins Center for Eating Disorders (D.M.), Greenwich, Connecticut 06831

Address all correspondence and requests for reprints to: Karen K. Miller, M.D., Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114. E-mail: kkmiller{at}partners.org

Abstract

Anorexia nervosa (AN), a psychiatric disease characterized by chronic starvation, is complicated by severe bone loss (1), for which there is no effective, available therapy. Although bone resorption is markedly increased in these patients, estrogen is an ineffective anti-resorptive therapy in the setting of undernutrition. We hypothesized bisphosphonate administration would result in a decrease in bone resorption and an increase in bone density in women with AN and bone loss, despite undernutrition. We therefore administered risedronate 5 mg daily for nine months to 10 women with AN, all of whom had osteopenia (mean AP spine T score: –2.7 ± 2) and compared NTX and bone density with baseline values and with those from available control data prospectively followed for the same time period. Bone density increased significantly in patients who received risedronate compared with controls and compared with baseline, despite lack of significant weight gain, for an increase of AP spine bone density of 4.1 ± 1.6% at six months and 4.9 ± 1.0% at nine months. Bone resorption, as measured by NTX, decreased 23.8% at one month and 29.6% at three months, from the high-normal to mid-normal range of young women. Our data suggest that risedronate 5 mg daily administered to women with AN and osteopenia may increase in bone density at the AP spine despite low weight. This is the first study to demonstrate marked increases in bone density in women with AN. Because of the lack of data regarding the safety of such medications in women of reproductive age, bisphosphonates are not approved in the U.S. for premenopausal women other than those receiving glucocorticoids. Further studies are needed to establish the efficacy and safety of bisphosphonate therapy in this population.

This article has been cited by other articles:

				M. P. WARREN and A. T. CHUA Exercise-Induced Amenorrhea and Bone Health in the Adolescent Athlete Ann. N.Y. Acad. Sci., June 1, 2008; 1135(1): 244 - 252. [Abstract] [Full Text] [PDF]

				J. Dominguez, L. Goodman, S. Sen Gupta, L. Mayer, S. F. Etu, B T. Walsh, J. Wang, R. Pierson, and M. P Warren Treatment of anorexia nervosa is associated with increases in bone mineral density, and recovery is a biphasic process involving both nutrition and return of menses Am. J. Clinical Nutrition, July 1, 2007; 86(1): 92 - 99. [Abstract] [Full Text] [PDF]

				V. BRUNI, M. FRANCESCA FILICETTI, and V. PONTELLO Open Issues in Anorexia Nervosa: Prevention and Therapy of Bone Loss Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 91 - 102. [Abstract] [Full Text] [PDF]

				K. J. Loud and C. M. Gordon Adolescent bone health. Arch Pediatr Adolesc Med, October 1, 2006; 160(10): 1026 - 1032. [Abstract] [Full Text] [PDF]

				N. H. Golden, E. A. Iglesias, M. S. Jacobson, D. Carey, W. Meyer, J. Schebendach, S. Hertz, and I. R. Shenker Alendronate for the Treatment of Osteopenia in Anorexia Nervosa: A Randomized, Double-Blind, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3179 - 3185. [Abstract] [Full Text] [PDF]